CLOs on the Move


 
Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts.   We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening.   Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.numirabio.com
  • 420 E. South Temple Suite 520
    Salt Lake City, UT USA 84111
  • Phone: 801.320.0682

Executives

Name Title Contact Details

Similar Companies

Travere Therapeutics

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife

Shasqi

Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood based diseases.

Salk Institute

Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.

Boundless Bio

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.